Many cancer types are caused by gene fusions that bring together parts of two different genes, often changing the activity of one of the partners. Although fusion transcripts result from structural variants on the DNA level such as translocations, inversions, or deletions, detection through DNA sequencing can be challenging due to the somewhat random nature of the rearrangements. RNA-level analysis with panel enrichment provides scientists with a more direct determination of the fusion and the biological consequence in fixed and paraffin embedded clinical specimens that can contain degraded material with potentially low tumor content.
Download this application note from Twist Biosciences and CeGaT to learn about fusion detection panels that cover relevant targets for therapeutic development, tumor diagnostics, and beyond.
